WeVote
Log In

Bill

Bill

SB 432

RELATING TO EQUITABLE GENDER REPRESENTATION ON CORPORATE BOARDS.

2025 Regular Session Introduced by Carol Fukunaga and 3 co-sponsors

SB 432 classifies 7-Hydroxymitragynine as a Schedule I drug and imposes strict penalties for xylazine trafficking, enhancing Florida's controlled substances regulations.

Carried over to 2026 Regular Session.
#corporateboards #dcca #genderrepresentation #penalties #reports
0
WeVote Research Nonpartisan
Bill Summary · SB 432

Summary of SB 432 - Controlled Substances

Bill Overview

Bill Number: SB 432
Title: Controlled Substances
Status: Filed
Introduced: November 07, 2025
Sponsor: Senator Yarborough
Effective Date: July 1, 2026

SB 432 is a legislative proposal aimed at amending Florida's controlled substances laws, specifically targeting the classification and regulation of certain substances, including 7-Hydroxymitragynine and xylazine.

Purpose and Intent

The primary intent of SB 432 is to enhance the regulation of controlled substances in Florida by:
- Adding 7-Hydroxymitragynine to the list of Schedule I controlled substances.
- Establishing stricter penalties for the sale, manufacture, or delivery of xylazine, a drug often used in veterinary medicine but increasingly associated with illicit drug use.

Key Provisions

  1. Addition of 7-Hydroxymitragynine:

    • This substance will be classified as a Schedule I controlled substance, indicating a high potential for abuse and no accepted medical use in treatment.

  2. Regulation of Xylazine:

    • The bill amends section 893.13 of the Florida Statutes to impose criminal penalties for the sale, manufacture, or delivery of xylazine.
    • A mandatory minimum term of imprisonment will be required for offenders.
    • The bill creates a new offense of trafficking in xylazine, with penalties that include mandatory minimum prison sentences and fines that vary based on the quantity involved.

  3. Exemptions:

    • The bill specifies that certain xylazine animal drug products approved by the United States Food and Drug Administration (FDA) are exempt from these regulations when used for approved purposes.

Impact

  • Individuals and Entities Affected:

    • The legislation will primarily affect individuals involved in the sale or distribution of 7-Hydroxymitragynine and xylazine, including drug dealers and manufacturers.
    • Veterinary practices using xylazine for legitimate purposes may need to navigate new regulations to ensure compliance.

  • Law Enforcement and Judicial System:

    • Increased responsibilities for law enforcement agencies to monitor and enforce the new regulations.
    • Potential increase in cases related to trafficking and possession of the newly classified substances, impacting the judicial system.

Procedural Aspects

  • The bill is currently in the filing stage and will undergo further legislative processes before becoming law.
  • If passed, the provisions will take effect on July 1, 2026, allowing time for law enforcement and the public to adjust to the new regulations.

Conclusion

SB 432 represents a significant step in Florida's efforts to combat substance abuse by tightening regulations on specific controlled substances. By classifying 7-Hydroxymitragynine as a Schedule I drug and imposing strict penalties for xylazine-related offenses, the bill aims to address the growing concerns surrounding these substances in the state.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.